🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

RecruitingPhase 4Ages 18 Years - 80 YearsAllNational Institute of Cardiovascular Diseases, Pa…
NCT07536802 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All patients with acute STEMI undergoing primary PCI * Patients of either sex, ≥18 years of age. Exclusion Criteria: * STEMI patients with cardiogenic shock at presentation * Patients with heart block * Allergy to adenosine * Patients refuse to give consent for participation
💊

What it tests

  • Adenosine pre-medication
  • Standard care
📍

Where

2 sites
National Institute of Cardiovascular Diseases
Karachi, Pakistan
National Institute of Cardiovascular Diseases
Karachi, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy